Abbott India Limited is a prominent healthcare company in India, delivering innovative solutions across multiple healthcare segments. Established in 1910, Abbott India has grown into a trusted leader in healthcare products and solutions, spanning medical devices, diagnostics, nutrition, and pharmaceuticals.
The company operates through four key segments: Medical Devices, Diagnostics, Nutrition, and Pharmaceuticals. Abbott India’s business model focuses on innovation and sustainable growth, providing advanced healthcare solutions while ensuring consistent returns for investors. Its diverse product portfolio ranges from life-saving diagnostics to consumer-focused nutrition and cutting-edge medical devices.
Abbott India's medical devices division offers cardiovascular devices, diabetes care products such as glucose monitoring systems, and neuromodulation devices for managing chronic pain and movement disorders. The diagnostics segment provides laboratory and point-of-care testing systems, molecular diagnostic solutions, and reagents for detecting infectious diseases and metabolic disorders.
The nutrition segment features products for infant, adult, and therapeutic nutrition, including brands such as Ensure® and Glucerna®. The pharmaceuticals segment provides a broad range of branded formulations across cardiology, neurology, gastroenterology, and metabolic disorders.
Abbott India has shown consistent financial performance, with FY 2024 revenue of ₹11,500 Crore, reflecting steady growth across its segments. The company continues to maintain profitability with strong margins and growing earnings per share.
Key financial metrics for recent periods include:
- FY 2024 revenue: ₹11,500 Crore (approx. 9% YoY growth)
- Q4 2024 revenue: ₹3,200 Crore (approx. 10% YoY growth)
- FY 2024 EPS: ₹130
- Q1 2025 EPS: ₹33
The Medical Devices segment has been a key driver, particularly in diabetes care, while Nutrition continues to grow due to strong brand demand. Diagnostics faced challenges due to reduced COVID-19 testing, but core diagnostic sales remain healthy with double-digit growth in select categories.
Abbott India maintains a strong focus on innovation, leveraging R&D to bring new products and treatment options to the market. Flagship products include FreeStyle Libre® glucose monitoring systems, structural heart devices, and advanced diagnostic kits.
Management anticipates FY 2025 growth of 7–8% in core operations, supported by operational efficiencies and product launches. Adjusted margins are expected to improve, reflecting continued focus on sustainable profitability. Earnings projections indicate a steady rise in EPS, affirming Abbott India’s growth trajectory.
Abbott India has a consistent dividend record, rewarding shareholders with stable returns. The company offers a quarterly dividend of ₹9.50 per share, representing an annual yield of around 1.7%, with the upcoming Ex-Date on July 15, 2025. Abbott India’s dividend growth over the past five years has averaged 10% per annum, reflecting strong shareholder commitment.
Abbott India continues to combine healthcare innovation with operational excellence, positioning itself as a market leader in India while delivering value to investors across its diversified healthcare portfolio.
